Description

Technical Parameters

Introduction

raws

product-1400-1400

Products Description

#### **1. Introduction**

Anastrozole is a highly effective non-steroidal aromatase inhibitor, widely used in the adjuvant treatment of hormone receptor-positive breast cancer. As a third-generation aromatase inhibitor, it significantly reduces the risk of recurrence by inhibiting estrogen synthesis and has become one of the core drugs for breast cancer treatment. This article will systematically analyze Anastrozole API from multiple dimensions, including chemical properties, pharmacological mechanisms, production processes, quality control, clinical applications, and market prospects.

#### **2. Chemical and physical properties**

1. **Basic information**

- **Chemical name**: 2,2'-[5-(1H-1,2,4-Triazol-1-ylmethyl)-1,3-phenylene]bis(2-methylpropiononitrile)

- **CAS number**: 120511-73-1

- **Molecular formula**: C17H19N5

- **Molecular weight**: 293.36 g/mol

- **Appearance**: White to off-white crystalline powder

- **Solubility**: Easily soluble in organic solvents (such as methanol, DMSO), slightly soluble in water (<0.1 mg/mL).

2. **Chemical structure characteristics**

- The core structure is a triazole ring connected to a benzene ring through a methylene group, and the side chain contains a cyanomethyl group, which gives it high selectivity and aromatase binding ability.

- The non-steroidal structure avoids steroid-related side effects.

3. **Stability**

- **Photosensitivity**: Need to be stored away from light (2-8℃ refrigerated).

- **pH tolerance**: Stable under acidic conditions, easy to degrade in alkaline environment.

#### **3. Pharmacological effects and clinical advantages**

1. **Mechanism of action**

- **Aromatase inhibition**: Selectively binds to cytochrome P450 aromatase, blocks the conversion of androstenedione to estrone, and reduces plasma estrogen levels (estrone in postmenopausal women decreases by 80%).

- **High specificity**: No effect on adrenal cortical hormone synthesis, reducing side effects.

2. **Clinical advantages**

- **Significant efficacy**: Compared with tamoxifen, the 5-year disease-free survival rate is increased by 3-5%.

- **Good tolerability**: No estrogen agonist effect, reducing the risk of endometrial cancer.

- **Convenient medication**: 1 mg orally per day, high patient compliance.

#### **4. Production process and technology optimization**

1. **Synthesis route**

- **Key intermediate**: 2,5-dibromotoluene is used as the starting material, cyano group is introduced by Grignard reaction, and then condensed with 1H-1,2,4-triazole.

- **Catalytic process**: Palladium catalyst catalyzes Suzuki coupling reaction to optimize yield (up to 75% or more).

2. **Process optimization**

- **Green chemistry**: Solvent-free microwave synthesis technology is used to reduce waste.

- **Purification technology**: Supercritical fluid chromatography (SFC) improves purity to 99.9%.

#### **5. Quality control and standards**

1. **Key detection indicators**

- **Purity**: HPLC method determines the main component ≥99.5%.

- **Impurity control**: Known impurities (such as decyano derivatives) ≤0.15%.

- **Microbial limit**: Meets USP<61> standards.

2. **International Pharmacopoeia Standard**

- **USP**: Moisture content ≤ 0.5%, ignition residue ≤ 0.1%.

- **EP**: Heavy metal content ≤ 20 ppm.

#### **6. Clinical application and side effect management**

1. **Indications**

- **Early breast cancer**: Postoperative adjuvant therapy to reduce recurrence.

- **Metastatic breast cancer**: First-line endocrine therapy.

2. **Dosage and course of treatment**

- **Standard dose**: 1 mg per day for 5 years.

- **Special population**: Patients with impaired liver function need to reduce the dose.

3. **Side effects and countermeasures**

- **Common reactions**: Joint pain (30%), hot flashes (20%).

- **Bone health management**: It is recommended to supplement calcium/vitamin D and monitor bone density regularly.

#### **7. Market analysis and future prospects**

1. **Global market overview**

- **Major manufacturers**: AstraZeneca (original research), China Huahai Pharmaceutical, India Cipla, etc.

- **Market size**: Global sales will exceed US$1 billion in 2023, with generic drugs accounting for 70%.

2. **Development trend**

- **Development of new dosage forms**: Long-acting injections and transdermal patches to improve convenience.

- **Combination therapy**: Combined with CDK4/6 inhibitors (such as Palbociclib) to enhance efficacy.

- **Exploration of new indications**: Clinical trials for prostate cancer and endometriosis are ongoing.

#### **8. Conclusion**

Anastrozole continues to lead the field of endocrine therapy for breast cancer with its high efficiency and safety. With the innovation of production processes and the expansion of indications, the demand for its raw materials will continue to grow, driving the progress of the global anti-cancer drug market.